EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient‐derived xenograft models of ALK + ALCL reveal preclinical promise for therapy with brigatinib

Nina Prokoph, Jamie D Matthews, Ricky M Trigg, Ivonne A Montes-Mojarro, G A Amos Burke iD, Falko Fend, Olaf Merkel, Lukas Kenner, Birgit Geoerger, Robert Johnston, Matthew J Murray iD, Charlotte Riguad und 2 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Nina Prokoph und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lymphoma, Large-Cell, Anaplastic, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Institut National Du Cancer, NIHR Cambridge Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic large‐cell lymphoma (ALCL) is a T‐cell malignancy predominantly driven by the oncogenic anaplastic lymphoma kinase (ALK), accounting for approximately 15% of all paediatric non‐Hodgkin lymphoma. Patients with central nervous system (CNS) relapse are particularly difficult to treat with a 3‐year overall survival of 49% and a median survival of 23.5 months. The second‐generation ALK inhibitor brigatinib shows superior penetration of the blood–brain barrier unlike the first‐generation drug crizotinib and has shown promising results in ALK+ non‐small‐cell lung cancer. However, the benefits of brigatinib in treating aggressive paediatric ALK+ ALCL are largely unknown. We established a patient‐derived xenograft (PDX) resource from ALK+ ALCL patients at or before CNS relapse serving as models to facilitate the development of future therapies. We show in vivo that brigatinib is effective in inducing the remission of PDX models of crizotinib‐resistant (ALK C1156Y, TP53 loss) ALCL and furthermore that it is superior to crizotinib as a second‐line approach to the treatment of a standard chemotherapy relapsed/refractory ALCL PDX pointing to brigatinib as a future therapeutic option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLymphoma, Large-Cell, AnaplasticLung NeoplasmsChildHumansAnaplastic Lymphoma KinaseCrizotinibReceptor Protein-Tyrosine KinasesHeterograftsNeoplasm Recurrence, LocalOrganophosphorus CompoundsProtein Kinase InhibitorsPyrimidines

Stichwörter der Autor:innen

ALCLPDXbrigatinibcrizotinibtyrosine kinase inhibitors

Substanzen

Anaplastic Lymphoma KinaseCrizotinibReceptor Protein-Tyrosine KinasesOrganophosphorus CompoundsProtein Kinase InhibitorsbrigatinibPyrimidines

Autor:innen und Institutionen

  • Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany.
  • Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
  • Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria.
  • Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: G A Amos Burke, Matthew J Murray, Suzanne D Turner

Förderung

  • Cancer Research UK
  • Institut National Du Cancer
  • NIHR Cambridge Biomedical Research Centre

Zitieren

APA

Prokoph, N., Matthews, J. D., Trigg, R. M., Montes-Mojarro, I. A., Burke, G. A. A., Fend, F., Merkel, O., Kenner, L., Geoerger, B., Johnston, R., Murray, M. J., Riguad, C., Brugières, L., & Turner, S. D. (2023). Patient‐derived xenograft models of ALK + ALCL reveal preclinical promise for therapy with brigatinib. British Journal of Haematology. https://doi.org/10.1111/bjh.18953

Vancouver

Prokoph N, Matthews JD, Trigg RM, Montes-Mojarro IA, Burke GAA, Fend F, et al. Patient‐derived xenograft models of ALK + ALCL reveal preclinical promise for therapy with brigatinib. British Journal of Haematology. 2023. doi:10.1111/bjh.18953

BibTeX
@article{Prokoph2023,
  author = {Prokoph, Nina and Matthews, Jamie D and Trigg, Ricky M and Montes-Mojarro, Ivonne A and Burke, G A Amos and Fend, Falko and Merkel, Olaf and Kenner, Lukas and Geoerger, Birgit and Johnston, Robert and Murray, Matthew J and Riguad, Charlotte and Brugières, Laurence and Turner, Suzanne D},
  title = {Patient‐derived xenograft models of ALK + ALCL reveal preclinical promise for therapy with brigatinib},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18953}
}
Kostenlos starten →